Partners

Rohto Pharmaceutical Co., Ltd

 Rohto is an ideal partner to develop Signum’s lead STM as well as future STM compounds. The synergies in this alliance are strong because Signum and Rohto have complementary strengths. Signum has strong basic and applied research; Rohto excels in actual product development. Signum is resource constrained and wants to develop strong products quickly; Rohto has large financial and product-development resources it can deploy rapidly. Rohto is a Japan-based company that manufactures and sells a wide range of products including skincare, eye care, and oral medicines. Headquartered in Osaka, Rohto has 20 subsidiaries and five associated companies, giving them broad reach in the Japanese consumer markets. We will jointly develop new applications and products for Arazine™ and solidify the research partnership by establishing a Signum laboratory in Rohto’s RVK (Research Village Kyoto) facility. Our partnership will contribute to Rohto’s strategic goals, while enhancing the commercial, business development and market focus of Signum’s technologies. We look forward to a productive and long term relationship.   

http://www.rohto.co.jp/global/

Princeton University

Signum has extensive ongoing interaction with the Research laboratory of Dr. Jeffry Stock in the Dept. of Molecular Biology. Signum licensed its foundational PP2A and AFC technology from Dr. Stock's laboratory and his laboratory continues to do basic research to elucidate the underlying biochemistry of these systems. Dr. Stock's laboratory has been able to perform various sophisticated tests on some of Signum's active agents, and continues to be a source of knowledge and expertise.

http://www.molbio1.princeton.edu/stock/index.php?option=com_frontpage&Itemid=1

University of Medicine and Dentistry of New Jersey

Dr. M. Maral Mouradian, MD, is a William Dow Lovett Professor of Neurology at UMDNJ-Robert Wood Johnson Medical School. Her current research focuses on the molecular pathogenesis of Parkinson's disease with an emphasis on the mechanisms by which pathogenic gene products cause neurodegeneration in cellular and mouse models of Parkinson’s disease. In collaboration with Signum, Dr. Mouradian will provide use of these models to help test promising new compounds with the goal of developing new therapeutic strategies for treating Parkinson’s disease.

http://umg.umdnj.edu/public/directory/doctor.asp?doctor=110207754

University of Pennsylvania: School of Medicine

Dr. Angela Haczku’s laboratory has established various in vitro and in vivo (mouse) model systems suitable to study pulmonary inflammation as well as the resulting changes in lung physiology. In collaboration, Signum and Dr. Haczku’s laboratory will assess the effects of GPM compounds on airway inflammation.

http://www.uphs.upenn.edu/lungctr/paccd/pulmonary/physicians_staff/faculty/ahaczku.html

UCLA, School of Dentistry

Our CEO Dr. Gregory Stock is also the Director of the Program on Medicine, Technology, and Society at UCLA’s School of Public Health. Signum’s tie to UCLA also extends to its School of Dentistry, were together we are looking for potential oral applications of Arazine^™ and other GPM molecules.

http://uclasod.dent.ucla.edu/

Dow Pharmaceutical Sciences, Inc.

Dow is one of the world’s leading experts in topical formulation and product development. Dow has created several different formulations to enhance penetration of our topically applied compounds. Here at Signum we perform in vitro penetration studies to test these formulations and based on our results consult with Dow for ways to further improve penetration.

http://www.dowpharm.com/

Weill Medical College of Cornell University and University of Pittsburgh

In collaboration with Richard Granstein, Chairman of the Department of Dermatology at the Weill Medical College of Cornell University and Dr. Suzan Obagi, assistant professor in dermatology at the University of Pittsburgh and Director of the Cosmetic Surgery and Skin Health Center, Signum will soon be starting a three-month, double-blinded, multi-center trial to better document anecdotal observations that daily use of Arazine® over several weeks noticeably reduces the redness associated with rosacea.

http://www.cornellphysicians.com/rgranstein/
http://www.upmc.edu/dermatology/patientinfo/Obagi.htm